Dammam | BETH – Abdullah Al-Shammari
In a step that reflects Saudi Arabia’s leadership in adopting cutting-edge global healthcare solutions, Dammam Medical Complex—a key facility within Eastern Health Cluster—has announced the availability of Lenacapavir, an advanced HIV treatment, for the first time within facilities affiliated with the Ministry of Health and the Health Holding Company.

A Breakthrough in Patient-Centered Care

Dr. Ali Al-Saeed, Consultant of Infectious Diseases at Dammam Medical Complex, described this milestone as a major leap forward in HIV care. He highlighted that the introduction of Lenacapavir aligns with the latest global medical research and significantly improves quality of life for patients by reducing both psychological and physical burdens associated with the disease.

Long-Acting, High-Impact Treatment

Lenacapavir belongs to the newest generation of antiretroviral medications for HIV, featuring an innovative mechanism of action that allows it to be administered at extended intervals. This improves patient adherence and enhances long-term clinical outcomes.

Dr. Al-Saeed emphasized that the adoption of this treatment reflects the health sector’s dedication to Saudi Arabia’s national transformation journey, and its growing status as a regional hub for cutting-edge therapeutic protocols.

A Model of Institutional Integration

This achievement was made possible through the collaborative efforts of various departments and specialized teams, most notably the Pharmacy Department, Supply Chain, and Administrative Support, presenting a model of effective institutional synergy aimed at enhancing care quality.

The initiative directly supports the Ministry of Health’s and the Health Holding Company’s vision of building a modern, patient-centered healthcare ecosystem, grounded in innovation, efficiency, and sustainability.

Treatment Launch Next Week

The administration of Lenacapavir will begin next week for eligible patients within advanced treatment programs, following strict medical guidelines and regulatory standards. This development brings a renewed sense of hope and broader therapeutic possibilities, supporting improved patient response and long-term management of HIV in the Kingdom.